Core Viewpoint - Yiqiao Shenzhou Technology Co., Ltd. reported a revenue of 324 million yuan for the first half of 2025, marking a year-on-year increase of 6.15%, and a net profit attributable to shareholders of 67.69 million yuan, with a non-recurring net profit of 33.12 million yuan, showing a significant growth of 31.85% [1] Group 1: Financial Performance - The company achieved a non-recurring net profit growth of 31.85%, indicating a recovery in performance post-pandemic, with the second quarter showing a quarter-on-quarter increase of 189% [1] - Yiqiao Shenzhou has maintained a consistent revenue scale and profitability since its listing, with a net profit of 1.128 billion yuan in 2020 prior to its IPO [2] - The company has accumulated nearly 4 billion yuan in current assets and over 1.1 billion yuan in undistributed profits [2] Group 2: Dividend Policy - Yiqiao Shenzhou announced its first mid-year dividend plan, proposing a cash dividend of 40 yuan per 10 shares, totaling 487 million yuan [1] - The company has consistently returned profits to investors through dividends for four consecutive years, aligning with regulatory policies advocating for normalized dividend mechanisms [2] - The act of distributing dividends reflects the company's stable profitability and cash flow, signaling management's confidence in future growth [2][3] Group 3: Industry Context - The bioreagent industry is characterized by high gross margins, short production cycles, and strong cash flow, allowing for rapid revenue generation [2] - The sector is experiencing significant growth driven by high technical barriers, rigid market demand, and supportive policies, leading to high added value and scale effects compared to traditional industries [3]